Technical Analysis for LPCN - Lipocine Inc.

Grade Last Price % Change Price Change
D 1.59 4.61% 0.07
LPCN closed up 4.61 percent on Friday, February 26, 2021, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical LPCN trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 4.61%
Below Lower BB Weakness 4.61%
Lower Bollinger Band Touch Weakness 4.61%
Oversold Stochastic Weakness 4.61%
50 DMA Resistance Bearish -3.05%
Older End-of-Day Signals for LPCN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 1 day ago
Down 2 % 1 day ago
Rose Above Lower Bollinger Band 1 day ago
Down 1% 1 day ago
Up 5% 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lipocine Inc. Description

Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Alcohols Metabolism Bypass Ketones Testosterone Androstanes Testosterone Replacement Therapy

Is LPCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.42
52 Week Low 0.3
Average Volume 4,601,595
200-Day Moving Average 1.45
50-Day Moving Average 1.69
20-Day Moving Average 1.82
10-Day Moving Average 1.76
Average True Range 0.17
ADX 22.76
+DI 17.21
-DI 30.09
Chandelier Exit (Long, 3 ATRs ) 1.78
Chandelier Exit (Short, 3 ATRs ) 1.97
Upper Bollinger Band 2.13
Lower Bollinger Band 1.50
Percent B (%b) 0.14
BandWidth 34.35
MACD Line -0.04
MACD Signal Line 0.02
MACD Histogram -0.0554
Fundamentals Value
Market Cap 104.44 Million
Num Shares 65.7 Million
EPS -0.55
Price-to-Earnings (P/E) Ratio -2.89
Price-to-Sales 286.68
Price-to-Book 7.20
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.85
Resistance 3 (R3) 1.84 1.74 1.81
Resistance 2 (R2) 1.74 1.68 1.75 1.79
Resistance 1 (R1) 1.67 1.64 1.71 1.68 1.78
Pivot Point 1.57 1.57 1.59 1.57 1.57
Support 1 (S1) 1.49 1.50 1.53 1.50 1.40
Support 2 (S2) 1.39 1.46 1.40 1.39
Support 3 (S3) 1.32 1.39 1.37
Support 4 (S4) 1.33